What is FathomX?
FathomX is a Digital Health AI spin-off originating from the National University of Singapore and National University Health System. Founded by esteemed researchers Prof Mikael Hartman and Prof Feng Meng Ling, the company's core offering is FxMammo, an AI Assistant engineered to revolutionize mammogram screening. This advanced technology aims to improve diagnostic accuracy by reducing both false positive and false negative rates, while simultaneously streamlining clinical workflow efficiency. FathomX primarily targets the Asia Pacific region, a market experiencing a substantial increase in demand for cutting-edge healthcare technology. The company's innovative approach has also earned it recognition as a portfolio company within the MedTech JUMPStart Program.
How much funding has FathomX raised?
FathomX has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2022): $1.6M, investors not publicly disclosed
What's next for FathomX?
With the recent major strategic investment, FathomX is poised for accelerated growth and market expansion. The enterprise-level capital infusion is expected to fuel further development of its AI capabilities, enhance its go-to-market strategy within the Asia Pacific, and potentially explore new clinical applications. This backing signifies strong confidence in FathomX's potential to disrupt the medical imaging sector and improve patient outcomes through AI-powered diagnostics. The company's trajectory suggests a focus on scaling operations and solidifying its position as a leader in digital health AI.
See full FathomX company page
